Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy

Blood Adv. 2022 Oct 11;6(19):5546-5549. doi: 10.1182/bloodadvances.2021006689.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • Humans
  • Interferon-alpha / adverse effects
  • Leukemia, Myeloid, Acute* / chemically induced
  • Leukemia, Myeloid, Acute* / drug therapy
  • Nucleosides* / therapeutic use

Substances

  • Antiviral Agents
  • Interferon-alpha
  • Nucleosides